Truven Health Analytics MarketScan Databases for Clinical Research in Colon and Rectal Surgery

Kulaylat, Audrey S.; Schaefer, Eric; Messaris, Evangelos; Hollenbeak, Christopher S.

doi:10.1055/s-0038-1673354

Cited by 102 publications

(49 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, larger employers typically contribute to this database compared to small- or medium-sized firms. 23 Additionally, we were unable to determine whether depression/anxiety medications were used for treatment of musculoskeletal pain or specifically targeting the coded mental illness. We are unable to assess whether extenuating circumstances resulting in the absence to psychological therapy sessions, such as missing psychological therapy sessions in favor of physical therapy treatments.…”

Section: Discussionmentioning

confidence: 99%

Psychological Healthcare Burden Lessens After Hip Arthroscopy for Those With Comorbid Depression or Anxiety

Zacharias

Lemaster

Hawk

et al. 2021

Arthroscopy, Sports Medicine, and Rehabilitation

View full text Add to dashboard Cite

In this study, we investigated whether patients undergoing arthroscopic treatment of femoral acetabular impingement syndrome (FAIS) seek health care for treatment of comorbid depression and anxiety in the year following hip arthroscopy. Methods: Using the Truven Health Marketscan database, FAIS patients who underwent hip arthroscopy between January 2009 and December 2016 were identified. Claims related to depression or anxiety filed during the year before surgery were required for inclusion. Using claims for pharmaceutical and psychological therapy treatments for mental health disorders, four groups of patients were analyzed on the basis of preoperative anxiety/depression treatment: medication only, therapy only, medication þ therapy, and no treatment. Number of opioid pain prescriptions within 180 days prior to surgery and >90 days after hip arthroscopy were also compared. Results: Depression and anxiety claims were identified in 5,208/14,830 (35.1%) patients. Preoperative treatment for depression and anxiety included medication only (n ¼ 648, 12.4%), therapy only (n ¼ 899, 17.3%), medication þ therapy (n ¼ 252, 4.8%), and no treatment (n ¼ 3,409, 65.5%). Of the 900 patients who filled an anxiety/depression-related prescription prior to surgery, 422 (46.9%) patients did not fill a similar prescription in the postoperative year. Of the 1,151 patients receiving anxiety/depressionrelated therapy prior to surgery, 549 (47.7%) did not receive therapy in the postoperative year. Preoperative opioid prescriptions were filled for 393 patients (60.6%) in medication-only group, 275 (30.6%) in therapy-only group, 156 (61.9%) in medication þ therapy group, and 1,059 (31.1%) in the group receiving no treatment. Opioid prescriptions >90 days postoperatively were filled for 330 (50.9%), 225 (25.0%), 120 (47.6%), and 861 (25.3%) patients, respectively. Conclusion: Hip arthroscopy for FAIS is associated with a decreased postoperative use of health care resources for the treatment of depression and anxiety. Clinicians should also be aware of the potential interplay between preoperative psychotropic medication use and prolonged opioid use when counseling patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Psychological Healthcare Burden Lessens After Hip Arthroscopy for Those With Comorbid Depression or Anxiety

Zacharias

Lemaster

Hawk

et al. 2021

Arthroscopy, Sports Medicine, and Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Despite some potential limitations regarding the representativeness, the MarketScan database provides a reliable source of real-world data and has previously been used in published epidemiological analyses of incidence and prevalence [ 26 , 27 ], safety [ 28 ], adherence [ 29 ], and healthcare utilization [ 24 , 25 ]. Over 900 peer-reviewed publications have incorporated MarketScan data, and the use of these data has increased greatly in the last decade [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study

Butler

Heeg

Holl

et al. 2021

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background Both interferon beta-1b (IFN-β-1b) and interferon beta-1a (IFN-β-1a) are immunomodulators that require regular subcutaneous self-administration by patients with multiple sclerosis (MS). However, no electronic autoinjector is available for IFN-β-1a in the US. Objective This retrospective cohort study investigated adherence to two subcutaneous disease-modifying therapies, IFN-β-1b and IFN-β-1a, during two periods (before and after the introduction of the BETACONNECT ® autoinjector for IFN-β-1b). Patients and Methods Data were evaluated from the MarketScan database for adults in the US with an MS diagnosis and a medical claim for subcutaneous IFN-β-1b or IFN-β-1a, either before (October 2013-September 2015 or after the introduction of BETACONNECT (October 2016-September 2018. Patient populations were propensity-score matched by demographic and clinical characteristics. Persistence was recorded, and adherence was evaluated by medication possession ratio (MPR). ResultsThe study included 196 IFN-β-1b and 365 IFN-β-1a people with MS (PwMS) (pre-BETACONNECT period), and 126 IFN-β-1b and 223 IFN-β-1a PwMS (post-BETACONNECT period). In the pre-BETACONNECT period, the proportion with at least 80% MPR was higher for IFN-β-1a (90%) than for IFN-β-1b (83%), but in the post-BETACONNECT period the proportion with ≥ 80% MPR was higher for IFN-β-1b (92%) than for IFN-β-1a (86%). In the pre-BETACONNECT period, median persistence (in days) was higher for than for , while in post-BETACONNECT period persistence was higher for IFN-β-1b (327) than for IFN-β-1a (229). Conclusions Following the introduction of BETACONNECT, this exploratory study suggested that PwMS taking IFN-β-1b were more adherent compared with those taking IFN-β-1a, with higher persistence, and more than 90% reached 80% MPR, a threshold commonly used to define good adherence.

show abstract

“…Consequently, results of this analysis may not be generalizable to patients with other insurance (eg, Medicaid, Medicare) or patients without health insurance coverage. That being said, a recent study by Kulaylat et al 57 discussed the relevance of MarketScan databases for clinical research. Second, while statistical analysis was conducted to adjust for patients’ characteristics, systemic differences may still exist between patients with advanced liver diseases and adjustment were limited to those characteristics that can be measured from administrative claims.…”

Section: Discussionmentioning

confidence: 99%

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases

Wong

Kachru

Martínez

et al. 2020

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

Truven Health Analytics MarketScan Databases for Clinical Research in Colon and Rectal Surgery

Cited by 102 publications

References 11 publications

Psychological Healthcare Burden Lessens After Hip Arthroscopy for Those With Comorbid Depression or Anxiety

Psychological Healthcare Burden Lessens After Hip Arthroscopy for Those With Comorbid Depression or Anxiety

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases

Contact Info

Product

Resources

About